Basic Stats
| LEI | 549300I3DV7F8OXPNA12 |
| CIK | 1053691 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CervoMed Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 11, 2025 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 11, 2025 |
Exhibit 99.1 CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to control arm over 32 weeks, which improved further among patients who have minimal evidence of Alzheimer’s disease (AD) |
|
| August 8, 2025 |
CervoMed 2025 Equity Incentive Plan Exhibit 10.5 CERVOMED INC. 2025 EQUITY INCENTIVE PLAN 1. Purpose of Plan. The purpose of the CervoMed Inc. 2025 Equity Incentive Plan (the “Plan”) is to advance the interests of CervoMed Inc. (the “Company”) and its stockholders by enabling the Company and its Subsidiaries to attract and retain qualified individuals to perform services for the Company and its Subsidiaries, providing incentive comp |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37942 CervoMed In |
|
| August 8, 2025 |
Separation Agreement, by and between the Company and Robert J. Cobuzzi, PhD, dated July 1, 2025 Exhibit 10.4 Separation Agreement The proposed terms and conditions of your separation from employment are as follows: 1. Your separation from CervoMed is effective as of the Separation Date. 2. If you elect to sign this Agreement, you will be eligible for the following payments and benefits (in addition to those stated above) in exchange for your undertakings set forth in Paragraph 3 below: a. Se |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 5, 2025 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 28, 2025 |
Exhibit 99.1 CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 July 28, 2025 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 25, 2025 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 23, 2025 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 19, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 19, 2025 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 12, 2025 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 12, 2025 |
Sales Agreement, by and between the Company and Leerink Partners, LLC, dated May 12, 2025 Exhibit 1.1 CervoMed Inc. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT May 12, 2025 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: CervoMed Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1. Issuance and Sale of Shares. The |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37942 CervoMed I |
|
| May 12, 2025 |
Up to $50,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-282494 PROSPECTUS SUPPLEMENT (To Prospectus Dated October 10, 2024) Up to $50,000,000 Shares of Common Stock We have entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), relating to the sale of shares of our common stock, par value $0.001 per share (“common stock”) offered by this prospectus. In |
|
| May 12, 2025 |
Exhibit 99.1 CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory a |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 18, 2025 |
Exhibit 10.2 EXECUTION VERSION EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of May 1, 2025 (the “Effective Date”) by and between CervoMed Inc. (the “Company”) and Mark De Rosch, PhD, FRAPS (the “Executive”). Recitals WHEREAS, the Company and the Executive previously entered into that certain offer letter, dated as of October 28, 2024, pursuant to which the C |
|
| April 18, 2025 |
Exhibit 10.1 EXECUTION VERSION AMENDED & RESTATED EMPLOYMENT AGREEMENT This Amended & Restated Employment Agreement (this “Agreement”) is entered into and effective as of April 16, 2025 (the “Effective Date”) by and between CervoMed Inc. (the “Company”) and Kelly Blackburn (the “Executive”). Recitals WHEREAS, the Company and the Executive previously entered into that certain employment agreement, |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 April 14, 2025 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 18, 2025 |
Form of Separation Agreement by and between the Company and Robert J. Cobuzzi, Jr., Ph.D. Exhibit 10.3 [], 2025 Separation Agreement The proposed terms and conditions of your separation from employment are as follows: 1. Your separation from CervoMed is effective as of the Separation Date. 2. If you elect to sign this Agreement, you will be eligible for the following payments and benefits (in addition to those stated above) in exchange for your undertakings set forth in Paragraph 3 bel |
|
| April 7, 2025 |
Exhibit 99.1 Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025 During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical Global |
|
| April 7, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 April 2, 2025 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 18, 2025 |
Exhibit 99.1 CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates -Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial’s primary outcome measure- -Plan to initiate Phase 3 trial in mid-2026 following meeting with regulatory aut |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 March 17, 2025 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 17, 2025 |
Exhibit 21.1 SIGNIFICANT SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Direct or Indirect Ownership Interest by Company EIP Pharma, Inc. DE 100% Diffusion Pharmaceuticals LLC VA 100% |
|
| March 17, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CervoMed Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per share |
|
| March 17, 2025 |
Form of Inducement Non-Qualified Stock Option Agreement. Exhibit 10.10 STOCK OPTION AGREEMENT This STOCK OPTION AGREEMENT (this “Agreement”) is entered into and effective as of [], 202[] (the “Grant Date”) by and between CervoMed Inc., a Delaware corporation (the “Company”), and [] (“Optionee”). A. The Company desires to grant a non-qualified stock option to purchase shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) |
|
| March 17, 2025 |
As filed with the Securities and Exchange Commission on March 17, 2025 As filed with the Securities and Exchange Commission on March 17, 2025 Registration No. |
|
| March 17, 2025 |
CervoMed Inc. Insider Trading Policy, effective as of March 14, 2025 Exhibit 19.1 CERVOMED INC. AMENDED AND RESTATED INSIDER TRADING POLICY CervoMed Inc. has adopted the attached policy prohibiting directors, officers, employees and consultants (and their immediate family members, other household members and controlled entities) from trading in securities of CervoMed, and in certain cases, the securities of other companies, while in possession of undisclosed materi |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37942 CervoMed Inc. |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 March 11, 2025 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 10, 2025 |
Exhibit 99.1 CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rati |
|
| March 10, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 March 10, 2025 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number |
|
| February 14, 2025 |
EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedu |
|
| January 31, 2025 |
Presentation of CervoMed Inc., dated January 31, 2025. Exhibit 99.2 |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 January 31, 2025 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 31, 2025 |
Exhibit 99.1 CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference — Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently manufactured batch of neflamapimod — — Pharmacokinetic |
|
| December 10, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 December 10, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Num |
|
| December 10, 2024 |
Exhibit 99.1 CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies —Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks— —Favorable safety and tolerability results with no new safety signal identified— —Target plasma drug concentrations not achieved during 16-wee |
|
| December 10, 2024 |
Corporate Presentation of CervoMed Inc. dated December 10, 2024. Exhibit 99.2 |
|
| December 3, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 December 3, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 27, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 27, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 27, 2024 |
Exhibit 99.1 CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders On track to report topline data from the RewinD-LB Phase 2b clinical trial in early-stage de |
|
| November 13, 2024 |
Exhibit 99.1 CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in October 2024; topline data expected in December 2024 – - Hosted a virtual key opinion leader event in July 2024 highlighting neflamapimod |
|
| November 13, 2024 |
Exhibit 99.2 CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval The award to CervoMed recognizes the advances made by the company towards developing the first treatment for Dementia with Lewy bodies (DLB) Bo |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 8, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 13, 2024 |
Exhibit 99.3 CervoMed Announces Key Senior Leadership Appointments - New hires in key scientific and regulatory roles to advance continued development of neflamapimod - Boston – November 13, 2024 – CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported two senior leadership appointments to advance continued devel |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37942 CervoM |
|
| November 4, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 4, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 4, 2024 |
Exhibit 99.1 CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity in DLB Neflamapimod treatment previously led to significant |
|
| October 30, 2024 |
Exhibit 99.1 CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC conference in January 2025 Boston, October 29, 2024 – CervoMed Inc. (NASDAQ: CRVO), a clinical-stage com |
|
| October 30, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 October 29, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 16, 2024 |
Exhibit 99.1 CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB) - On track to report topline data from the Phase 2b trial in December 2024 - Neflamapimod has the potential to restore function and improve cognitive and motor functions in DLB patients - 96% of patients enrolled in RewinD-LB completed |
|
| October 16, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 October 15, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 11, 2024 |
424B3 1 crvo20241008d424b3.htm FORM 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-282494 PROSPECTUS $250,000,000 CERVOMED INC. Common Stock Preferred Stock Debt Securities Warrants Units Rights to Purchase Common Stock, Preferred Stock, Debt Securities or Units We may offer and sell from time to time shares of our common stock; shares of our preferred stock; debt securities, which ma |
|
| October 10, 2024 |
CERVOMED INC. 4,728,916 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279343 PROSPECTUS CERVOMED INC. 4,728,916 Shares of Common Stock This prospectus relates to the resale from time to time, by the selling stockholders identified in this prospectus or their donees, pledgees, assignees, transferees, distributees or other successors-in-interest (the “selling stockholders”) up to an aggregate of 4,728,916 shares of |
|
| October 8, 2024 |
CERVOMED INC. 20 Park Plaza Suite 424 Boston, MA 02116 CERVOMED INC. 20 Park Plaza Suite 424 Boston, MA 02116 October 8, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, DC 20549 Attention: Chris Edwards Re: CervoMed Inc. Registration Statement on Form S-3 (File No. 333-282494) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Reg |
|
| October 3, 2024 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 October 1, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 3, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) CervoMed Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities |
|
| October 3, 2024 |
As filed with the Securities and Exchange Commission on October 3, 2024. As filed with the Securities and Exchange Commission on October 3, 2024. Registration No. 333-279343 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CERVOMED INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorp |
|
| October 3, 2024 |
As filed with the Securities and Exchange Commission on October 3, 2024. As filed with the Securities and Exchange Commission on October 3, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CERVOMED INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 30-0645032 (I.R.S. Employer |
|
| October 1, 2024 |
Press Release, issued September 26, 2024 Exhibit 99.1 CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) Plasma biomarker data from AscenD-LB Phase 2a study and baseline data from the RewinD-LB Phase 2b study to be featured in late-breaking oral presentations at CTAD Boston, September 26, 2024 – CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on develop |
|
| October 1, 2024 |
Exhibit 99.1 CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) Plasma biomarker data from AscenD-LB Phase 2a study and baseline data from the RewinD-LB Phase 2b study to be featured in late-breaking oral presentations at CTAD Boston, September 26, 2024 – CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on develop |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 September 26, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 1, 2024 |
5,064,570 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No.: 333-279343 PROSPECTUS SUPPLEMENT No. 5 (to the Prospectus dated June 5, 2024, as supplemented by Prospectus Supplement No. 1, dated June 14, 2024, Prospectus Supplement No. 2, dated July 12, 2024, Prospectus Supplement No. 3, dated August 1, 2024, and Prospectus Supplement No. 4, dated August 9, 2024) 5,064,570 Shares of Common Stock This prospect |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 12, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 15, 2024 |
Exhibit 99.1 CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - Completed enrollment in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in June 2024; topline data expected in December 2024 - - Hosted a virtual key opinion leader event in July 2024 highlighting neflamapimod’s potential fo |
|
| August 9, 2024 |
Calculation of Filing Fee Table. EX-FILING FEES 4 ex710763.htm EXHIBIT FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CervoMed Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration F |
|
| August 9, 2024 |
Exhibit 10.2 AMENDED & RESTATED EMPLOYMENT AGREEMENT This Amended & Restated Employment Agreement (this “Agreement”) is entered into effective as of June 1, 2024 (the “Effective Date”), by and between CervoMed Inc. (the “Company”) and William Elder (the “Executive”). Recitals WHEREAS, the Company and the Executive previously entered into that certain Employment Agreement, dated as of September 23, |
|
| August 9, 2024 |
5,064,570 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No.: 333-279343 PROSPECTUS SUPPLEMENT No. 4 (to the Prospectus dated June 5, 2024, as supplemented by Prospectus Supplement No. 1, dated June 14, 2024, Prospectus Supplement No. 2, dated July 12, 2024, and Prospectus Supplement No. 3, dated August 1, 2024) 5,064,570 Shares of Common Stock This prospectus supplement No. 4 (the “Prospectus Supplement”) a |
|
| August 9, 2024 |
Exhibit 10.4 CONSULTING AGREEMENT This Consulting Agreement is made as of June 1, 2024, between CervoMed Inc. ("CervoMed"), and J. William Tanner (“Tanner”). 1. (a) Tanner has been employed by CervoMed as an employee pursuant to the terms of an Employment Agreement between CervoMed and Tanner. Tanner’s employment with CervoMed will conclude effective May 31, 2024. CervoMed has offered to Tanner a |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 S-8 1 crvo20240808s8.htm FORM S-8 As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 30-0645032 (State or other jurisdiction of incorporation o |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37942 CervoMed In |
|
| August 9, 2024 |
Exhibit 10.3 May 15, 2024 Separation Agreement The proposed terms and conditions of your separation from employment are as follows: 1. Your separation from CervoMed is effective as of May 31, 2024. 2. If you elect to sign this Separation Agreement (“Agreement”), you will be eligible for the following payments and benefits (in addition to those stated above) in exchange for your undertakings set fo |
|
| August 1, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 July 29, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 1, 2024 |
CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference Exhibit 99.2 CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference Boston – July 30, 2024 – CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s Management will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, to be held in Boston, M |
|
| August 1, 2024 |
Press Release, issued July 29, 2024 Exhibit 99.1 CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB) - Baseline data from the AscenD-LB Phase 2a trial in DLB demonstrated that plasma glial fibrillary acidic protein (GFAP) was highly correlated to scores on the CDR-SB; plasma GFAP shown to |
|
| August 1, 2024 |
5,064,570 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No.: 333-279343 PROSPECTUS SUPPLEMENT No. 3 (to the Prospectus dated June 5, 2024, as supplemented by Prospectus Supplement No. 1, dated June 14, 2024, and Prospectus Supplement No. 2, dated July 12, 2024) 5,064,570 Shares of Common Stock This prospectus supplement No. 3 (the “Prospectus Supplement”) amends and supplements our prospectus contained in o |
|
| August 1, 2024 |
Press Release, issued July 30, 2024 Exhibit 99.2 CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference Boston – July 30, 2024 – CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s Management will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, to be held in Boston, M |
|
| August 1, 2024 |
Exhibit 99.1 CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB) - Baseline data from the AscenD-LB Phase 2a trial in DLB demonstrated that plasma glial fibrillary acidic protein (GFAP) was highly correlated to scores on the CDR-SB; plasma GFAP shown to |
|
| July 23, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 July 23, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 12, 2024 |
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024 Exhibit 99.1 CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024 - Phase 2b RewinD-LB trial of neflamapimod for the treatment of dementia with Lewy bodies is fully enrolled with topline data expected in December 2024 BOSTON, July 11, 2024 (GLOBE NEWSWIRE) - CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age- |
|
| July 12, 2024 |
5,064,570 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No.: 333-279343 PROSPECTUS SUPPLEMENT No. 2 (to the Prospectus dated June 5, 2024, as supplemented by Prospectus Supplement No. 1 dated June 14, 2024) 5,064,570 Shares of Common Stock This prospectus supplement No. 2 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form S-1, effective as of |
|
| July 12, 2024 |
Press Release, issued July 11, 2024 Exhibit 99.1 CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024 - Phase 2b RewinD-LB trial of neflamapimod for the treatment of dementia with Lewy bodies is fully enrolled with topline data expected in December 2024 BOSTON, July 11, 2024 (GLOBE NEWSWIRE) - CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age- |
|
| July 12, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 July 11, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 14, 2024 |
5,064,570 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No.: 333-279343 PROSPECTUS SUPPLEMENT No. 1 (To the Prospectus dated June 5, 2024) 5,064,570 Shares of Common Stock This prospectus supplement No. 1 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form S-1, effective as of June 5, 2024 (the “Prospectus”), related to the resale by the sellin |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 11, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 14, 2024 |
Exhibit 99.1 CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies - Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value indication expected with positive result - Boston – June 11, 2024 – CervoMed Inc. (NASDAQ: CRVO), a clini |
|
| June 14, 2024 |
Press Release, issued June 11, 2024 Exhibit 99.1 CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies - Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value indication expected with positive result - Boston – June 11, 2024 – CervoMed Inc. (NASDAQ: CRVO), a clini |
|
| June 6, 2024 |
5,064,570 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279343 PROSPECTUS 5,064,570 Shares of Common Stock This prospectus relates to the resale from time to time, by the selling stockholders identified in this prospectus or their donees, pledgees, assignees, transferees, distributees or other successors-in-interest (the “selling stockholders”) of up to an aggregate of 5,064,570 shares of our common |
|
| June 3, 2024 |
CERVOMED INC. 20 Park Plaza Suite 424 Boston, MA 02116 CERVOMED INC. 20 Park Plaza Suite 424 Boston, MA 02116 June 3, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, DC 20549 Attention: Doris Stacey Gama Re: CervoMed Inc. Registration Statement on Form S-1, as amended (File No. 333-279343) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General |
|
| May 30, 2024 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 30, 2024 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 30, 2024 Registration No. |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 17, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 20, 2024 |
Exhibit 10.3 CONSULTING AGREEMENT This Consulting Agreement is made as of [], 2024, between CervoMed Inc. ("CervoMed"), and J. William Tanner (“Tanner”). 1. (a) Tanner has been employed by CervoMed as an employee pursuant to the terms of an Employment Agreement between CervoMed and Tanner. Tanner’s employment with CervoMed will conclude effective May 31, 2024. CervoMed has offered to Tanner a Sepa |
|
| May 20, 2024 |
Exhibit 10.1 AMENDED & RESTATED EMPLOYMENT AGREEMENT This Amended & Restated Employment Agreement (this “Agreement”) is entered into effective as of June 1, 2024 (the “Effective Date”), by and between CervoMed Inc. (the “Company”) and William Elder (the “Executive”). Recitals WHEREAS, the Company and the Executive previously entered into that certain Employment Agreement, dated as of September 23, |
|
| May 20, 2024 |
Exhibit 10.2 May [], 2024 Separation Agreement The proposed terms and conditions of your separation from employment are as follows: 1. Your separation from CervoMed is effective as of May 31, 2024. 2. If you elect to sign this Separation Agreement (“Agreement”), you will be eligible for the following payments and benefits (in addition to those stated above) in exchange for your undertakings set fo |
|
| May 20, 2024 |
CervoMed to Appoint William Elder as Chief Financial Officer Exhibit 99.1 CervoMed to Appoint William Elder as Chief Financial Officer Boston – May 20, 2024 – CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Se |
|
| May 15, 2024 |
Exhibit 99.1 CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates - CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024- - Completed up to $149.4 million private placement with leading healthcare investors in early 2Q 20 |
|
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 15, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 00 |
|
| May 10, 2024 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 10, 2024 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 10, 2024 Registration No. |
|
| May 10, 2024 |
Exhibit 10.19 CERVOMED INC. SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made as of March 28, 2024 (the “Effective Date”), by and between CERVOMED INC., a Delaware corporation (the “Company”), and each of the purchasers whose names are set forth on Schedule A hereto (each, a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, the Purchasers desire to |
|
| May 10, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) CervoMed Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1)(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Fees to Be Pai |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 23, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 April 22, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 11, 2024 |
CRVO / CervoMed Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CervoMed Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15713L109 (CUSIP Number) April 1, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| April 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 April 1, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 5, 2024 |
Exhibit 99.1 CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates - Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the end of 2025 - Cervo |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 April 4, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 29, 2024 |
Form of Indemnification Agreement between CervoMed Inc. and each of its directors and officers Exhibit 10.12 INDEMNIFICATION AGREEMENT This Indemnification Agreement (the “Agreement”) is made and entered into this []th day of [], 202[], by and between CervoMed Inc., a Delaware corporation (the “Company,” which term shall include, where appropriate, any Entity (as hereinafter defined) controlled directly or indirectly by the Company), and [] (the “Indemnitee”). WHEREAS, it is essential to th |
|
| March 29, 2024 |
Exhibit 4.15 |
|
| March 29, 2024 |
Exhibit 10.11 STOCK OPTION AGREEMENT This STOCK OPTION AGREEMENT (this “Agreement”) is entered into and effective as of [], 202[] (the “Grant Date”) by and between CervoMed Inc., a Delaware corporation (the “Company”), and [] (“Optionee”). A. The Company has adopted (i) EIP Pharma Inc. 2018 Employee, Director and Consultant Equity Incentive Plan (as such plan may be amended from time to time, the |
|
| March 29, 2024 |
Exhibit 21.1 SIGNIFICANT SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Direct or Indirect Ownership Interest by Company EIP Pharma, Inc. DE 100% Diffusion Pharmaceuticals LLC VA 100% |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37942 CervoMed Inc. |
|
| March 29, 2024 |
Exhibit 97.1 CERVOMED INC. CLAWBACK POLICY I. Introduction The Board of Directors (the “Board”) of CervoMed Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this |
|
| March 29, 2024 |
Description of Securities of CervoMed Inc. Exhibit 4.16 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of CervoMed Inc. (“us,” “our,” “we,” “CervoMed,” or the “Company”) is a summary of certain rights of holders of our capital stock and certain provisions of our certificate of incorporation, as amended (the “Charter”), and our bylaws, as amended (the “Bylaws”), in each case, as currently in effect. This summary |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 March 28, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 28, 2024 |
Form of 2024 Private Placement Pre-Funded Warrant Exhibit 4.1 THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE |
|
| March 28, 2024 |
Exhibit 99.1 CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital $50 million financing upfront with up to an additional $99.4 million tied to exercise of warrants Pro forma cash and cash equivalents from upfront proceeds |
|
| March 28, 2024 |
Exhibit 10.1 CERVOMED INC. SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made as of March 28, 2024 (the “Effective Date”), by and between CERVOMED INC., a Delaware corporation (the “Company”), and each of the purchasers whose names are set forth on Schedule A hereto (each, a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, the Purchasers desire to |
|
| March 28, 2024 |
Form of 2024 Private Placement Series A Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 March 12, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 6, 2024 |
EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree that the Statement on Schedule 13G to which this Exhibit is attached is filed on behalf of each of them. Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached. Each of them is responsible for the |
|
| March 6, 2024 |
CRVO / CervoMed Inc. / AI EIPP Holdings LLC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CervoMed Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15713L109 (CUSIP Number) March 5, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 March 5, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 5, 2024 |
Exhibit 99.1 CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024 - Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP) - Neflamapimod effects on GFAP correlated to clinical outcomes assessed by CDR Sum |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 February 26, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 28, 2024 |
CRVO / CervoMed Inc. / BOGER JOSHUA S - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* CervoMed Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15713L 109 (CUSIP Number) Joshua S. Boger, Ph.D. c/o CervoMed Inc. 20 Park Plaza, Suite 424 Boston, MA 02116 (617) 744-4400 (Name, Address and Telephon |
|
| February 28, 2024 |
Exhibit 4.2 AMENDMENT TO PRE-FUNDED COMMON STOCK PURCHASE WARRANT This Amendment, dated as of February 26, 2024 (this “Amendment”), by and between CervoMed Inc., a Delaware corporation (the “Company”), and The Joshua S. Boger 2021 Trust DTD 12/09/2021 (the “Holder”) amends that certain Pre-Funded Common Stock Purchase Warrant, dated as of August 16, 2023 (the “Warrant”), by and between the Company |
|
| February 14, 2024 |
CRVO / CervoMed Inc. / AI EIPP Holdings LLC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CervoMed Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15713L109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 14, 2024 |
EX-99.1 2 d789294dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree that the Statement on Schedule 13G to which this Exhibit is attached is filed on behalf of each of them. Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached. Each of |
|
| February 9, 2024 |
CRVO / CervoMed Inc. / BOGER JOSHUA S - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 CervoMed Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15713L 109 (CUSIP Number) Joshua S. Boger, Ph.D. c/o CervoMed Inc. 20 Park Plaza, Suite 424 Boston, MA 02116 (617) 744-4400 (Name, Address and Telephone Number of Person |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 February 5, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| February 7, 2024 |
Exhibit 99.1 CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 Boston – Februa |
|
| February 7, 2024 |
CervoMed to Participate in the Emerging Growth Conference 67 Exhibit 99.2 CervoMed to Participate in the Emerging Growth Conference 67 Boston – February 5, 2024 – CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company’s Management will provide a corporate update at the Emerging Growth Conference 67, to be held virtually from February 7-8, 2024. Presentation |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 February 1, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| February 2, 2024 |
Exhibit 10.1 EXECUTION VERSION AMENDED & RESTATED EMPLOYMENT AGREEMENT This Amended & Restated Employment Agreement (this “Agreement”) is entered into as of February 1, 2024 (the “Effective Date”) by and between CervoMed Inc. (the “Company”) and John Alam, M.D. (the “Executive”). Recitals WHEREAS, EIP Pharma, Inc., a wholly-owned subsidiary of the Company, and the Executive previously entered into |
|
| February 2, 2024 |
Exhibit 10.2 EXECUTION VERSION AMENDED & RESTATED EMPLOYMENT AGREEMENT This Amended & Restated Employment Agreement (this “Agreement”) is entered into as of February 1, 2024 (the “Effective Date”) by and between CervoMed Inc. (the “Company”) and Robert J. Cobuzzi, Jr., Ph.D. (the “Executive”). Recitals WHEREAS, the Company and the Executive previously entered into that certain Employment Agreement |
|
| February 2, 2024 |
Employment Agreement, dated as of February 1, 2024, by and between Kelly Blackburn and CervoMed Inc. Exhibit 10.3 EXECUTION VERSION EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of February 1, 2024 (the “Effective Date”) by and between CervoMed Inc. (the “Company”) and Kelly Blackburn (the “Executive”). Recitals WHEREAS, the Company and the Executive previously entered into that certain Offer Letter, dated as of April 29, 2018, as amended January 29, 2019, w |
|
| January 5, 2024 |
CervoMed to Participate in the Emerging Growth Conference 66 Exhibit 99.1 CervoMed to Participate in the Emerging Growth Conference 66 Boston – January 5, 2024 – CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company’s Management will provide a corporate update at the Emerging Growth Conference 66, to be held virtually from January 10-11, 2024. Presentation |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 January 5, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 January 4, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 December 21, 2023 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 15, 2023 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 17, 2023 |
Exhibit 10.1 EXECUTION VERSION EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of November 15, 2023 (the “Effective Date”) by and between CervoMed Inc. (the “Company”) and J. William Tanner (the “Executive”). Recitals WHEREAS, the Executive desires to accept employment with the Company upon the terms and conditions hereinafter set forth. NOW THEREFORE, in consi |
|
| November 13, 2023 |
Form of EIP Subscription Agreement, dated as of July 10, 2023 Exhibit 10.1 FORM OF SUBSCRIPTION AGREEMENT EIP PHARMA, INC. To: EIP Pharma, Inc. 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 This Subscription Agreement (the “Agreement”), dated July [], 2023, is made between EIP Pharma, Inc., a Delaware corporation (“we” or the “Company”), and the undersigned prospective purchaser (“you” or the “Undersigned”) who is subscribing for that number of shares |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 13, 2023 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 13, 2023 |
Exhibit 99.1 CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights Dosed first patient in Phase 2b RewinD-LB study evaluating neflamapimod in patients with dementia with Lewy bodies (DLB) Multiple peer-reviewed journal publications and a conference presentation inform on the potential of neflamapimod in DLB and probability of success in optimized RewinD-LB study Completed r |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 7, 2023 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-24477 30-0645032 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 October 25, 2023 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-24477 30-0645032 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 25, 2023 |
Corporate Presentation of CervoMed Inc. dated October 25, 2023. Exhibit 99.4 |
|
| October 25, 2023 |
Presentation, dated October 25, 2023. Exhibit 99.3 |
|
| October 25, 2023 |
Exhibit 99.2 CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies With incorporation of key learnings, Phase 2b has >95% (approaching 100%) statistical power to meet its primary endpoint: change in Clinical Dementia Rating Sum-of-Boxes (CDR-SB) vs. placebo New da |
|
| October 25, 2023 |
Exhibit 99.1 CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias Final publication in Neurology® of Phase 2a Results Stratified by Plasma Phosphorylated Tau Status at Baseline Strengthens the Case for Progressing Neflamapimod as a Disease-Modifying Treatment for Dementia with Lewy Bodies Res |
|
| October 25, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 October 24, 2023 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-24477 30-0645032 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 3, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 October 3, 2023 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-24477 30-0645032 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| September 29, 2023 |
Exhibit 99.3 CERVOMED INC. BUSINESS Unless the context otherwise requires, all references in this Exhibit 99.3 to “we,” “our,” “us,” or “CervoMed” refer to the business of CervoMed Inc. Overview We are a clinical stage therapeutics company that is developing treatments for acute and chronic neurodegenerative diseases of the brain and the Central Nervous System (“CNS”), such as Dementia with Lewy B |
|
| September 29, 2023 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 15, 2023 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-24477 30-0645032 (State or other jurisdiction of incorporation) (Commission File Num |
|
| September 29, 2023 |
Risks Related to CervoMed Inc. Exhibit 99.2 Risks Related to CervoMed Inc. Investing in CervoMed Inc. (the “Company,” “we” or “us”) securities involves a high degree of risk. Set forth below are certain material risks and uncertainties known to us that could adversely affect our business, financial condition, or results of operations or could cause our actual results to differ materially from our expectations expressed in our f |
|
| September 29, 2023 |
As filed with the Securities and Exchange Commission on September 29, 2023 As filed with the Securities and Exchange Commission on September 29, 2023 Registration No. |
|
| September 29, 2023 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CervoMed Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per share |
|
| September 29, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF EIP PHARMA’S FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF EIP PHARMA’S FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing in Exhibit 99.2 to the Current Report on Form 8-K, filed by CervoMed Inc. (“CervoMed”) with the SEC on August 9, 2 |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 September 6, 2023 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-24477 30-0645032 (State or other jurisdiction of incorporation) (Commission File Num |
|
| September 6, 2023 |
Exhibit 99.1 CervoMed Announces Publication in Neurology® Results Showing a Blood Test at Study Entry Identified Patients Who Demonstrated Substantial Response to Neflamapimod in Dementia with Lewy Bodies Additional protocol-specified analyses of the AscenD-LB Phase 2a results show that patients without elevated plasma ptau181 levels are more responsive than those with such elevation and have subs |
|
| September 6, 2023 |
Corporate Presentation, dated September 6, 2023 Exhibit 99.2 |
|
| August 28, 2023 |
Joint Filing Agreement, dated as of August 25, 2023. Exhibit 4 JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13D (as may be amended from time to time, the “Schedule 13D”) with respect to the common stock of CervoMed Inc. |
|
| August 28, 2023 |
CRVO / CervoMed Inc / ZAVRL FRANK - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 CervoMed Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15713L 109 (CUSIP Number) Frank E. Zavrl c/o CervoMed Inc. 20 Park Plaza, Suite 424 Boston, MA 02116 (617) 744-4400 (Name, Address and Telephone Number of Person Authoriz |
|
| August 28, 2023 |
CRVO / CervoMed Inc / ALAM JOHN J - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 CervoMed Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15713L 109 (CUSIP Number) John J. Alam, M.D. c/o CervoMed Inc. 20 Park Plaza, Suite 424 Boston, MA 02116 (617) 744-4400 (Name, Address and Telephone Number of Person Auth |
|
| August 28, 2023 |
EX-99.2 Exhibit 99.2 LIMITED POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lincoln Benet and Alejandro Moreno, and each of them individually, the undersigned’s true and lawful attorney-in-fact to: • execute for and on behalf of the undersigned, in the undersigned’s capacity as a beneficial owner of CervoMed Inc. (the “Company”): (i) Forms 3, 4 a |
|
| August 28, 2023 |
EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree that the Statement on Schedule 13G to which this Exhibit is attached is filed on behalf of each of them. Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached. Each of them is responsible for the |
|
| August 28, 2023 |
CRVO / CervoMed Inc / AI EIPP Holdings LLC - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CervoMed Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15713L109 (CUSIP Number) August 16, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| August 17, 2023 |
Exhibit 3.3 CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION (AS AMENDED) OF DIFFUSION PHARMACEUTICALS INC. DIFFUSION PHARMACEUTICALS INC., a corporation incorporated and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”) does hereby certify: FIRST: That, at a meeting of the Board of Directors of the Corporation (the “Board of Direc |
|
| August 17, 2023 |
Letter from KPMG LLP dated August 17, 2023. Exhibit 16.1 August 17, 2023 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for CervoMed Inc., formerly known as Diffusion Pharmaceuticals Inc., (the Company) and, under the date of March 24, 2023, we reported on the consolidated financial statements of Diffusion Pharmaceuticals Inc. as of and for the years ended December 31 |
|
| August 17, 2023 |
Exhibit 99.1 Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma Approximately 71% of Stockholders Voted in Favor of the Transaction Diffusion Announces 1-for-1.5 Reverse Stock Split Merger on Track to Close on August 16, 2023 CHARLOTTESVILLE, VA, August 15, 2023 – Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) today announced that its stockholders have voted to approve all propos |
|
| August 17, 2023 |
Form of Indemnification Agreement between the Company and each of its directions and officers. Exhibit 10.9 INDEMNIFICATION AGREEMENT This Indemnification Agreement (the “Agreement”) is made and entered into this day of , by and between CervoMed Inc. (f/k/a Diffusion Pharmaceuticals Inc.), a Delaware corporation (the “Company,” which term shall include, where appropriate, any Entity (as hereinafter defined) controlled directly or indirectly by the Company), and (the “Indemnitee”). WHEREAS, |
|
| August 17, 2023 |
-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 15, 2023 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 001-24477 30-0645032 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 17, 2023 |
Exhibit 3.2 CERTIFICATE OF MERGER OF DAWN MERGER SUB INC. (a Delaware corporation) WITH AND INTO EIP PHARMA, INC. (a Delaware corporation) Pursuant to Title 8, Section 251(c) of the General Corporation Law of the State of Delaware (the “DGCL”), the undersigned corporation, organized and existing under and by virtue of the DGCL, does hereby certify as follows: FIRST: The name and state of incorpora |
|
| August 17, 2023 |
Exhibit 99.2 CervoMed Announces Completion of Merger with EIP Pharma Shares of CervoMed to commence trading on Nasdaq under new ticker symbol "CRVO" on August 17, 2023 CervoMed will be focused on advancing oral stress kinase inhibitor neflamapimod for the treatment of dementia with Lewy bodies and other degenerative diseases of the brain CervoMed has a cash runway through Phase 2b clinical data wh |
|
| August 17, 2023 |
Bylaws, as amended, of CervoMed Inc. EXHIBIT 3.5 BYLAWS OF CERVOMED INC. (AS AMENDED) ARTICLE I OFFICES 1.1 Registered Office. The address of the registered office of CervoMed Inc. (the “Corporation”) in the State of Delaware shall be 615 South Dupont Hwy., Dover, Kent County, Delaware 19901. The name of the registered agent of the Corporation at that address is National Corporate Research, Ltd. 1.2 Other Offices. The Corporation may |
|
| August 17, 2023 |
Form of EIP 2018 Investor Warrant (AI EIPP Holdings LLC) Exhibit 4.2 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR ANY OTHER SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF (1) AN EFFECTIVE REGISTRATION STATEMENT COVERING THIS WARRANT UNDER THE ACT AND ANY OTHER APPLICABLE SECURITIES LAWS, OR (2) AN OPINION OF COUNSEL RE |
|
| August 17, 2023 |
Exhibit 3.4 CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION (AS AMENDED) OF DIFFUSION PHARMACEUTICALS INC. Diffusion Pharmaceuticals Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY THAT: FIRST: That, on August 8, 2023, the Board of Directors of the Corporation (the “Board”) |
|
| August 17, 2023 |
Form of 2023 Pre-Funded Investor Warrant Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 17, 2023 |
Form of EIP 2018 Investor Warrant Exhibit 4.1 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR ANY OTHER SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF (1) AN EFFECTIVE REGISTRATION STATEMENT COVERING THIS WARRANT UNDER THE ACT AND ANY OTHER APPLICABLE SECURITIES LAWS, OR (2) AN OPINION OF COUNSEL RE |
|
| August 14, 2023 |
Exhibit 99.1 EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies BOSTON – August 14, 2023 – EIP Pharma Inc. (“EIP Pharma” or the “Company”), a privately held clinical-stage company focused on developing treatments for neurodegenerative diseases, today announced that the first patient has been dosed in the Company’s Rewi |
|
| August 14, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 000-24477 30-0645032 (State or other jurisdiction of incorporation) (Com |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 000-24477 30-0645032 (State or other jurisdiction of incorporation) (Com |
|
| August 14, 2023 |
Exhibit 99.1 EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies BOSTON – August 14, 2023 – EIP Pharma Inc. (“EIP Pharma” or the “Company”), a privately held clinical-stage company focused on developing treatments for neurodegenerative diseases, today announced that the first patient has been dosed in the Company’s Rewi |
|
| August 9, 2023 |
Corporate Presentation of EIP Pharma, Inc. Exhibit 99.3 |
|
| August 9, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On March 30, 2023, Diffusion, Merger Sub, and EIP entered into the Merger Agreement, pursuant to which, among other things, and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into EIP at the Effective Time, with EIP continuing after the Merger as the surviving corpor |
|
| August 9, 2023 |
Exhibit 99.2 EIP Pharma, Inc. Financial Statements as of June 30, 2023 and 2022 EIP Pharma, Inc. Index to Financial Statements Balance Sheets (Unaudited) F-1 Statements of Operations (Unaudited) F-2 Statements of Changes in Convertible Preferred Stock and Stockholders’ Deficit (Unaudited) F-3 Statements of Cash Flows (Unaudited) F-4 Notes to Financial Statements (Unaudited) F-5 EIP Pharma, Inc. Ba |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 000-24477 30-0645032 (State or other jurisdiction of incorporation) (Comm |
|
| August 9, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On March 30, 2023, Diffusion, Merger Sub, and EIP entered into the Merger Agreement, pursuant to which, among other things, and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into EIP at the Effective Time, with EIP continuing after the Merger as the surviving corpor |
|
| August 9, 2023 |
Corporate Presentation of EIP Pharma, Inc. Exhibit 99.3 |
|
| August 9, 2023 |
Exhibit 99.2 EIP Pharma, Inc. Financial Statements as of June 30, 2023 and 2022 EIP Pharma, Inc. Index to Financial Statements Balance Sheets (Unaudited) F-1 Statements of Operations (Unaudited) F-2 Statements of Changes in Convertible Preferred Stock and Stockholders’ Deficit (Unaudited) F-3 Statements of Cash Flows (Unaudited) F-4 Notes to Financial Statements (Unaudited) F-5 EIP Pharma, Inc. Ba |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 000-24477 30-0645032 (State or other jurisdiction of incorporation) (Comm |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37942 DIFFUSION P |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 000-24477 30-0645032 (State or other jurisdiction of incorporation) (Comm |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 000-24477 30-0645032 (State or other jurisdiction of incorporation) (Comm |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 000-24477 30-0645032 (State or other jurisdiction of incorporation) (Comm |
|
| August 3, 2023 |
EIP Pharma to Present at Canaccord Genuity 43rd Annual Growth Conference Exhibit 99.1 EIP Pharma to Present at Canaccord Genuity 43rd Annual Growth Conference BOSTON, MA – August 3, 2023 – EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced that the Company’s senior management team will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9 at 4:00 p.m. ET. The Company |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 000-24477 30-0645032 (State or other jurisdiction of incorporation) (Comm |
|
| August 3, 2023 |
EIP Pharma to Present at Canaccord Genuity 43rd Annual Growth Conference Exhibit 99.1 EIP Pharma to Present at Canaccord Genuity 43rd Annual Growth Conference BOSTON, MA – August 3, 2023 – EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced that the Company’s senior management team will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9 at 4:00 p.m. ET. The Company |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 000-24477 30-0645032 (State or other jurisdiction of incorporation) (Commi |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 000-24477 30-0645032 (State or other jurisdiction of incorporation) (Commi |
|
| July 13, 2023 |
PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Stockholders of Diffusion Pharmaceuticals Inc. |
|
| July 12, 2023 |
Form of Proxy Card for Special Meeting of Diffusion Pharmaceuticals Inc. Exhibit 99.7 |
|
| July 12, 2023 |
DIFFUSION PHARMACEUTICALS INC. 300 East Main Street Suite 201 Charlottesville, Virginia 22902 DIFFUSION PHARMACEUTICALS INC. 300 East Main Street Suite 201 Charlottesville, Virginia 22902 July 12, 2023 VIA EDGAR Suzanne Hayes Dillon Haigus Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Diffusion Pharmaceuticals Inc. Registration Statement on Form S-4 (File No. 333-271823) Originally filed on May 11, 2023, as am |
|
| July 12, 2023 |
As filed with the U.S. Securities and Exchange Commission on July 11, 2023 Table of Contents As filed with the U.S. Securities and Exchange Commission on July 11, 2023 Registration No. 333-271823 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to Form S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 2834 30-0645032 (State or ot |
|
| July 12, 2023 |
Consent of Canaccord Genuity LLC, financial advisor to Diffusion Exhibit 99.8 Canaccord Genuity LLC 535 Madison Avenue New York, NY 10022 T1: 1.212.389.8000 cgf.com Consent of Canaccord Genuity LLC Board of Directors Diffusion Pharmaceuticals Inc. 300 East Main Street, Suite 201 Charlottesville, VA 22902 We hereby consent to the inclusion of our opinion letter, dated March 29, 2023, to the Board of Directors of Diffusion Pharmaceuticals Inc. (“Diffusion”) as An |
|
| July 12, 2023 |
Form of EIP 2023 Pre-Funded Warrant Exhibit 4.12 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| July 11, 2023 |
July 11, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| June 23, 2023 |
Director Consent (Sylvie Grégoire, PharmD.) Exhibit 99.2 DIRECTOR CONSENT I hereby consent to serve as a director of Diffusion Pharmaceuticals Inc. (the “Company”), if elected as such, and to be named as a nominee or potential nominee for director of the Company in any registration statement filed by the Company under the Securities Act of 1933, as amended, including all amendments and post-effective amendments or supplements thereto and an |
|
| June 23, 2023 |
Director Consent (John Alam, M.D.) Exhibit 99.1 DIRECTOR CONSENT I hereby consent to serve as a director of Diffusion Pharmaceuticals Inc. (the “Company”), if elected as such, and to be named as a nominee or potential nominee for director of the Company in any registration statement filed by the Company under the Securities Act of 1933, as amended, including all amendments and post-effective amendments or supplements thereto and an |
|
| June 23, 2023 |
Director Consent (Marwan Sabbagh, M.D.) Exhibit 99.4 DIRECTOR CONSENT I hereby consent to serve as a director of Diffusion Pharmaceuticals Inc. (the “Company”), if elected as such, and to be named as a nominee or potential nominee for director of the Company in any registration statement filed by the Company under the Securities Act of 1933, as amended, including all amendments and post-effective amendments or supplements thereto and an |
|
| June 23, 2023 |
Consent of Canaccord Genuity LLC, financial advisor to Diffusion Exhibit 99.8 Canaccord Genuity LLC 535 Madison Avenue New York, NY 10022 T1: 1.212.389.8000 cgf.com Consent of Canaccord Genuity LLC Board of Directors Diffusion Pharmaceuticals Inc. 300 East Main Street, Suite 201 Charlottesville, VA 22902 We hereby consent to the inclusion of our opinion letter, dated March 29, 2023, to the Board of Directors of Diffusion Pharmaceuticals Inc. (“Diffusion”) as An |
|
| June 23, 2023 |
Director Consent (Frank Zavrl) Exhibit 99.5 DIRECTOR CONSENT I hereby consent to serve as a director of Diffusion Pharmaceuticals Inc. (the “Company”), if elected as such, and to be named as a nominee or potential nominee for director of the Company in any registration statement filed by the Company under the Securities Act of 1933, as amended, including all amendments and post-effective amendments or supplements thereto and an |
|
| June 23, 2023 |
Director Consent (Jeff Poulton) Exhibit 99.3 DIRECTOR CONSENT I hereby consent to serve as a director of Diffusion Pharmaceuticals Inc. (the “Company”), if elected as such, and to be named as a nominee or potential nominee for director of the Company in any registration statement filed by the Company under the Securities Act of 1933, as amended, including all amendments and post-effective amendments or supplements thereto and an |
|
| June 23, 2023 |
As filed with the U.S. Securities and Exchange Commission on June 22, 2023 Table of Contents As filed with the U.S. Securities and Exchange Commission on June 22, 2023 Registration No. 333-271823 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to Form S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 2834 30-0645032 (State or ot |
|
| June 22, 2023 |
June 22, 2023 VIA EDGAR Suzanne Hayes Dillon Haigus United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 000-24477 30-0645032 (State or other jurisdiction of incorporation) (Commi |
|
| May 19, 2023 |
Exhibit 10.1 May 15, 2023 William Hornung Re: Separation from Employment and General Release Dear Bill, This letter agreement and general release (this “Agreement”) sets forth the terms of your separation from employment with Diffusion Pharmaceuticals Inc. (together with its subsidiaries, “Diffusion” or the “Company”) effective May 15, 2023 (the “Separation Date”). References in this Agreement to |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commis |
|
| May 19, 2023 |
Exhibit 10.1 May 15, 2023 William Hornung Re: Separation from Employment and General Release Dear Bill, This letter agreement and general release (this “Agreement”) sets forth the terms of your separation from employment with Diffusion Pharmaceuticals Inc. (together with its subsidiaries, “Diffusion” or the “Company”) effective May 15, 2023 (the “Separation Date”). References in this Agreement to |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-37942 30-0645032 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 000-24477 30-0645032 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2023 |
Corporate Presentation, dated May 15, 2023 Exhibit 99.1 |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 000-24477 30-0645032 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2023 |
Corporate Presentation, dated May 15, 2023 Exhibit 99.1 |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37942 DIFFUSION |
|
| May 11, 2023 |
Exhibit 10.30 John Alam President & CEO EIP Pharma, Inc. CONFIDENTIAL AND PERSONAL January 29, 2019 Kelly Blackburn 112 Grove Street Medford, MA 02155 Dear Kelly: EIP Pharma, Inc. (the “Company”) is pleased to raise the amount of your base salary to a rate of $240,000 per annum (the “Base Salary”), payable in semi-monthly installments of $10,000 and subject to applicable deductions and withholding |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 000-24477 30-0645032 (State or other jurisdiction of incorporation) (Commis |
|
| May 11, 2023 |
Exhibit 10.24 AMENDMENT NO. 1 OPTION AND LICENSE AGREEMENT This Amendment No. 1 (this “Amendment”) to that certain Option and License Agreement by and between EIP Pharma LLC, a Massachusetts limited liability company, with principal offices located at 11 Channing Street, Cambridge, MA 02138 (“EIP”) and Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, with principal offices located |
|
| May 11, 2023 |
Offer Letter, dated as of April 29, 2018, by and between EIP Pharma, Inc., and Kelly Blackburn Exhibit 10.29 John Alam President & CEO EIP Pharma, Inc. CONFIDENTIAL AND PERSONAL April 29, 2018 Kelly Blackburn 112 Grove Street Medford, MA 02155 Dear Kelly: EIP Pharma, Inc. (the “Company”) is pleased to offer you the position of Vice President Clinical Development commencing on or about May 14th, 2018. As Vice President of Clinical Development, you will be reporting to John Alam, President an |
|
| May 11, 2023 |
Director Consent (Frank Zavrl) Exhibit 99.5 DIRECTOR CONSENT I hereby consent to serve as a director of Diffusion Pharmaceuticals Inc. (the “Company”), if elected as such, and to be named as a nominee or potential nominee for director of the Company in any registration statement filed by the Company under the Securities Act of 1933, as amended, including all amendments and post-effective amendments or supplements thereto and an |
|
| May 11, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-4 (Form Type) DIFFUSION PHARMACEUTICALS INC. |
|
| May 11, 2023 |
Consent of Canaccord Genuity LLC, financial advisor to Diffusion Exhibit 99.8 Canaccord Genuity LLC 535 Madison Avenue New York, NY 10022 T1: 1.212.389.8000 cgf.com Consent of Canaccord Genuity LLC Board of Directors Diffusion Pharmaceuticals Inc. 300 East Main Street, Suite 201 Charlottesville, VA 22902 We hereby consent to the inclusion of our opinion letter, dated March 29, 2023, to the Board of Directors of Diffusion Pharmaceuticals Inc. (“Diffusion”) as An |
|
| May 11, 2023 |
EIP Pharma to Present at JMP Securities Life Sciences Conference Exhibit 99.1 EIP Pharma to Present at JMP Securities Life Sciences Conference BOSTON, MA – May 11, 2023 – EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced that the Company’s senior management team will present at the JMP Securities Life Sciences Conference on Monday, May 15 at 11:00 a.m. ET. The company will also be holding |
|
| May 11, 2023 |
Exhibit 10.27 AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment No. 1 to Executive Employment (the “Amendment”) is made and entered into as of March 4, 2019, by and between EIP Pharma, Inc. (the “Company”) and Sylvie Grégoire (the “Executive”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in that certain Executive |
|
| May 11, 2023 |
Director Consent (Jeff Poulton) Exhibit 99.3 DIRECTOR CONSENT I hereby consent to serve as a director of Diffusion Pharmaceuticals Inc. (the “Company”), if elected as such, and to be named as a nominee or potential nominee for director of the Company in any registration statement filed by the Company under the Securities Act of 1933, as amended, including all amendments and post-effective amendments or supplements thereto and an |
|
| May 11, 2023 |
Director Consent (John Alam, M.D.) Exhibit 99.1 DIRECTOR CONSENT I hereby consent to serve as a director of Diffusion Pharmaceuticals Inc. (the “Company”), if elected as such, and to be named as a nominee or potential nominee for director of the Company in any registration statement filed by the Company under the Securities Act of 1933, as amended, including all amendments and post-effective amendments or supplements thereto and an |
|
| May 11, 2023 |
Director Consent (Marwan Sabbagh, M.D.) Exhibit 99.4 DIRECTOR CONSENT I hereby consent to serve as a director of Diffusion Pharmaceuticals Inc. (the “Company”), if elected as such, and to be named as a nominee or potential nominee for director of the Company in any registration statement filed by the Company under the Securities Act of 1933, as amended, including all amendments and post-effective amendments or supplements thereto and an |
|
| May 11, 2023 |
Exhibit 10.25 AMENDMENT NO. 2 OPTION AND LICENSE AGREEMENT This Amendment No. 2 (this “Amendment”) to that certain Option and License Agreement by and between EIP Pharma LLC, a Massachusetts limited liability company, with principal offices located at 11 Channing Street, Cambridge, MA 02138 (“EIP”) and Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, with principal offices located |
|
| May 11, 2023 |
Exhibit 10.23 OPTION AND LICENSE AGREEMENT BY AND BETWEEN EIP PHARMA LLC AND VERTEX PHARMACEUTICALS INCORPORATED [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Table of Contents Page ARTICLE I DEFINITIONS 1 ARTICLE II OPTION GRANT AND |
|
| May 11, 2023 |
As filed with the U.S. Securities and Exchange Commission on May 10, 2023 Table of Contents As filed with the U.S. Securities and Exchange Commission on May 10, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 2834 30-0645032 (State or other jurisdiction of incorp |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 000-24477 30-0645032 (State or other jurisdiction of incorporation) (Commis |
|
| May 11, 2023 |
Exhibit 10.28 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), made and entered into this 2nd day of April, 2018 (the “Effective Date”), by and between EIP Pharma, Inc. (“Company”), and John Alam, M.D. (“Executive”). WHEREAS, Company wishes to employ Executive as its Chief Executive Officer; WHEREAS, Executive represents that Executive possesses the necessary s |
|
| May 11, 2023 |
Exhibit 10.26 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), made and entered into this 2nd day of April, 2018 (the “Effective Date”), by and between EIP Pharma, Inc. (“Company”), and Sylvie Gregoire (“Executive”). WHEREAS, Company wishes to employ Executive as its Executive Chair of the Board of Directors; WHEREAS, Executive represents that Executive possess |
|
| May 11, 2023 |
EIP Pharma, Inc. 2018 Employee, Director and Consultant Equity Incentive Plan Exhibit 10.31 EIP PHARMA, INC. 2018 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this EIP Pharma, Inc. 2018 Employee, Director and Consultant Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to a |
|
| May 11, 2023 |
EIP Pharma to Present at JMP Securities Life Sciences Conference Exhibit 99.1 EIP Pharma to Present at JMP Securities Life Sciences Conference BOSTON, MA – May 11, 2023 – EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced that the Company’s senior management team will present at the JMP Securities Life Sciences Conference on Monday, May 15 at 11:00 a.m. ET. The company will also be holding |
